Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that the expanding multi-resistant HIV population is in need of new classes of drugs. One such drug that could prove valuable to these patients is Trimeris' T-20, according to the new Pharmacor report, HIV.

(Photo: )

"The need for novel HIV drug therapies with activity in patients failing highly active antiretroviral therapy (HAART) is critical," said John Lebbos, M.D., senior analyst at Decision Resources. "Trimeris' T-20 will lead a new group of entry inhibitors in helping patients failing therapy with multi-class resistance. Used in conjunction with HAART, entry inhibitors, like Trimeris' T-20, its follow-up entry inhibitor T-1249, and Progenics' PRO 542, will generate nearly $1 billion in annual sales by 2011. Significant opportunities still remain in the traditional antiretroviral classes for agents with improved safety profiles and more convenient dosing."

Disease Background--HIV

Since its identification in the early 1980s, the human immunodeficiency virus (HIV) has established itself as one of the most serious epidemics of modern time and a significant source of morbidity, mortality, and cost to society. Since the late 1980s, advances in the understanding and treatment of HIV, particularly the development of highly active antiretroviral therapies (HAART), have substantially halted the progression of HIV disease and reduced mortality from acquired immunodeficiency syndrome (AIDS). In many patients, HAART has converted HIV from an invariably lethal infection to a chronic illness.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. HIV is an Infectious Disease report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Pfizer's Pregabalin May Not Be Enough to Save the Epilepsy Drug Market from Generic Erosion

View Now